A bold move bridges clinical trials and real-world care, redefining how software and medicine converge.

March 19, 2025 – Vélizy-Villacoublay, France — Dassault Systèmes has announced a strategic investment in Click Therapeutics, a pioneer in prescription digital therapeutics (PDTs) and software-enhanced (SE) drug therapies. This partnership deepens the role of Dassault Systèmes’ MEDIDATA brand in transforming the patient journey across the life sciences continuum—from virtual clinical trials to commercial digital health solutions.

With this investment, Dassault Systèmes is doubling down on its mission to reshape healthcare through integrated technology platforms, extending beyond the clinic to influence how patients engage with their treatments in daily life.

Bridging the Gap Between Trials and Treatment

The collaboration between MEDIDATA and Click Therapeutics aims to establish a gold standard for the design, execution, and commercialization of digital and pharmaceutical trials. By merging MEDIDATA’s clinical trial virtualization capabilities—powering over 8,000 active studies per year—with Click Therapeutics’ expertise in digital interventions, the partnership is poised to offer life science companies a unified framework for:

• Advancing prescription digital therapeutics and SE product approvals
• Supporting label expansions for existing pharmaceuticals
• Creating long-term, real-world evidence pipelines
• Improving patient engagement from post-trial monitoring through ongoing care

Redefining the Patient Experience

MEDIDATA has long been a leader in clinical data infrastructure, offering a fully virtualized platform that unites patients, providers, and manufacturers. This new collaboration expands that reach into real-world care, where software can now function not just as an aid to treatment—but as treatment itself.

By leveraging Dassault Systèmes’ global reach and life sciences virtualization expertise, Click Therapeutics can accelerate development and deployment of digital therapeutics to a global patient population.

What the Leaders Are Saying

“Digital therapeutics are beginning to transform the way customers think about their future clinical development programs,” said Anthony Costello, CEO of MEDIDATA. “Our partnership with Click Therapeutics enables our customers to take the fastest, most reliable path to bringing digital therapeutics to patients, helping to build a direct connection over a lifelong healthcare journey.”

“Since the FDA issued new guidance on Prescription Drug Use-Related Software, we’ve seen tremendous interest in software as medicine,” added David Benshoof Klein, CEO of Click Therapeutics. “Dassault Systèmes’ investment enables us to expand the boundaries of medicine and deliver truly next-generation solutions to patients.”

Why This Matters

This strategic alliance signals the continued convergence of biotechnology, data science, and digital health. It also highlights a growing trend: as regulatory frameworks evolve, major players are accelerating investments in digital-first therapies that can demonstrate measurable outcomes in both clinical and real-world settings.

The result? A more connected, personalized, and continuous healthcare experience for patients—supported by virtual platforms that transcend the traditional limits of drug therapy.